These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19347989)

  • 21. Effect of a national disaster on blood supply and safety: the September 11 experience.
    Glynn SA; Busch MP; Schreiber GB; Murphy EL; Wright DJ; Tu Y; Kleinman SH;
    JAMA; 2003 May; 289(17):2246-53. PubMed ID: 12734136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood safety in developing countries.
    Gibbs WN; Corcoran P
    Vox Sang; 1994; 67(4):377-81. PubMed ID: 7701809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
    Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
    Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priority needs and wisdom strategy for blood transfusion safety in developing low-resource countries.
    Abdelrazik AM; Ezzat Ahmed GM
    Transfus Apher Sci; 2016 Feb; 54(1):147-9. PubMed ID: 26874467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Donor exclusions, discarded blood and transfusion unsuited blood conserves of 2,13 million potential blood donors 1991 to 1994].
    Diekamp U; Wehrend W; Marklof E; Kamutzky K
    Beitr Infusionsther Transfusionsmed; 1996; 33():81-92. PubMed ID: 8974711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The History and Challenges of Blood Donor Screening in China.
    Li L; Li KY; Yan K; Ou G; Li W; Wang J; Song N; Tian L; Ji X; Chen Y; Liang X; Liu Z; Wu Y
    Transfus Med Rev; 2017 Apr; 31(2):89-93. PubMed ID: 28012709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan.
    Mine H; Emura H; Miyamoto M; Tomono T; Minegishi K; Murokawa H; Yamanaka R; Yoshikawa A; Nishioka K;
    J Virol Methods; 2003 Sep; 112(1-2):145-51. PubMed ID: 12951223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Availability, safety, and quality of blood for transfusion in the Americas.
    Cruz JR; Pérez-Rosales MD
    Rev Panam Salud Publica; 2003; 13(2-3):103-10. PubMed ID: 12744785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The History of the Foundation of the Iranian National Blood Transfusion Service in 1974 and the Biography of its Founder; Professor Fereydoun Ala.
    Azizi MH; Nayernouri T; Bahadori M
    Arch Iran Med; 2015 Jun; 18(6):393-400. PubMed ID: 26058940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidemiological surveillance of blood donors and residual risk of blood-borne infections in France, 2001 to 2003].
    Pillonel J; Le Marrec N; Girault A; David D; Laperche S
    Transfus Clin Biol; 2005 Jul; 12(3):239-46. PubMed ID: 15963749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of HIV transmission by blood transfusion in the developing world: achievements and continuing challenges.
    Lackritz EM
    AIDS; 1998; 12 Suppl A():S81-6. PubMed ID: 9632988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative strategies in assuring blood safety: An overview.
    Epstein JS
    Biologicals; 2010 Jan; 38(1):31-5. PubMed ID: 20110174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the confidential unit exclusion form: the Canadian Blood Services experience.
    O'Brien SF; Fan W; Xi G; Yi QL; Goldman M
    Vox Sang; 2010 Feb; 98(2):138-44. PubMed ID: 19754523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of COVID-19 on blood safety and availability in the Islamic Republic of Iran.
    Divkolaye N; Arabkhazaeli A; Hajibeigi B; Eshghi P
    East Mediterr Health J; 2022 Nov; 28(11):823-828. PubMed ID: 36515446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013.
    Keshvari M; Sharafi H; Alavian SM; Mehrabadi H; Zolfaghari S
    Transfus Apher Sci; 2015 Aug; 53(1):38-47. PubMed ID: 25892591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood transfusion practices and blood-banking services in a Kenyan hospital.
    Lackritz EM; Ruebush TK; Zucker JR; Adungosi JE; Were JB; Campbell CC
    AIDS; 1993 Jul; 7(7):995-9. PubMed ID: 8357559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries.
    Burnouf T; Epstein J; Faber JC; Smid WM;
    Vox Sang; 2024 Feb; 119(2):102-109. PubMed ID: 37872819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of the confidential unit exclusion option.
    Petersen LR; Lackritz E; Lewis WF; Smith DS; Herrera G; Raimondi V; Aberle-Grasse J; Dodd RY
    Transfusion; 1994 Oct; 34(10):865-9. PubMed ID: 7940657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.